tenacious in our search for transformative therapies
TARA-002
TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for multiple oncologic indications and lymphatic malformations (LMs). We are evaluating TARA-002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and LMs in the U.S.
IV CHOLINE CHLORIDE
FOR IFALD
An investigational phospholipid substrate replacement therapy for intestinal failure-associated liver disease (IFALD).
